A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Study ID
NCT02519348

Study type
Interventional

Study phase
Phase 2

Study status
Active, not recruiting

Trial Acronym

Trial Summary

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.

More informations

Trial Starting Date

Oct 19,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age 99 Years

Enrollement Limit

433